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ment was independent of residual fluid.  Message: Cross-
hair scans detect relevant collections of retinal fluid accu-
rately and may be sufficient in daily clinical practice. 
 © 2015 S. Karger AG, Basel 
 Introduction 
 Age-related macular degeneration (AMD) is a chronic 
and degenerative disease and represents the leading cause 
of legal blindness in white persons  [1] . The exudative (or 
wet) form presents with intra- (IRF) or subretinal fluid 
(SRF) because abnormal choroidal neovascularization 
leads to leakage of fluid into and underneath the neuro-
sensory retina. Current treatment options for the neovas-
cular component consist of anti-angiogenic substances 
that are able to reduce intra- and subretinal leakage and 
edema  [2–4] . Anti-vascular endothelial growth factor an-
tibodies such as ranibizumab (Lucentis; Genentech, Inc., 
South San Francisco, Calif., USA) have been shown to 
restore macular architecture to a remarkable degree, 
which often translates to a significant improvement of 
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 Abstract 
 Purpose: To assess intra- and subretinal fluid during the 
loading phase with intravitreal ranibizumab in exudative 
age-related macular degeneration and to quantify the accu-
racy of crosshair scan spectral-domain optical coherence 
 tomography with regard to retinal fluid.  Methods: This is a 
retrospective study of 31 treatment-naive patients who re-
ceived 3 monthly intravitreal ranibizumab injections. Visual 
acuity and the presence of retinal fluid were assessed at each 
visit using volume and crosshair scan protocols.  Results: Vi-
sual acuity improved and central retinal thickness decreased 
significantly during the loading phase. However, retinal fluid 
persisted in two thirds of the patients. The accuracy of the 
crosshair scan to detect fluid was 93%.  Conclusions: A 
 substantial proportion of eyes had persistent fluid after 3 
months of ranibizumab injections. However, visual improve-
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visual acuity  [5] . The initial treatment phase, the so-called 
loading phase, consisting of 3 monthly intravitreal injec-
tions of ranibizumab 0.5 mg/0.05 ml, has been shown to 
produce the major proportion of improvement in visual 
acuity and the main reduction of central retinal thickness 
(CRT) when assessed by optical coherence tomography 
(OCT)  [6] . Whereas most clinical trials assessed CRT as 
parameter for treatment efficacy, the presence of IRF 
and/or SRF in OCT imaging is more indicative of exuda-
tive activity in clinical practice and is a decisive factor for 
recommending continuation of treatment for exudative 
AMD.
 Using spectral-domain OCT (SD-OCT), discrete 
structures such as the photoreceptor inner/outer seg-
ments or the retinal pigment epithelium can be visual-
ized. The high resolution allows the detection of minimal 
morphological changes occurring in the course of AMD. 
Scans can be obtained either from a single vertical and 
horizontal line, or as a crosshair scan combining a vertical 
and a horizontal line scan intersecting at a point of inter-
est. Furthermore, owing to the short acquisition time of 
spectral-domain imaging, volume scans can be obtained 
from the central retina with high spatial resolution.
 The aim of this study was to assess the presence of IRF 
or SRF during the loading phase in patients with exuda-
tive AMD receiving intravitreal anti-vascular endothelial 
growth factor therapy, using SD-OCT. Furthermore, the 
accuracy of crosshair SD-OCT imaging to detect SRF or 
IRF was assessed against high-resolution volume scan-
ning as the gold standard.
 Methods 
 In this retrospective interventional case series, 31 consecutive 
patients receiving initial treatment with ranibizumab for exudative 
AMD were identified from the procedure logs at the Retinal Ser-
vice of the Department of Ophthalmology at the University Hos-
pital Bern, Switzerland. All patients had clinically confirmed exu-
dative AMD and had SD-OCT imaging performed before receiv-
ing treatment. Only treatment-naive patients were included in this 
study. The loading protocol was identical for all patients and con-
sisted of 3 monthly intravitreal injections of ranibizumab 0.5 
mg/0.05 ml, as previously reported  [7] .
 In addition to monthly SD-OCT imaging, best-corrected vi-
sual acuity (BCVA) was assessed monthly according to the ETDRS 
protocol with logMAR charts at 4 and 1 m, respectively. Spectralis 
SD-OCT (Heidelberg Engineering, Heidelberg, Germany, soft-
ware version 5.3) scans were acquired using an established proto-
col consisting of both a crosshair and a volume scan. The crosshair 
scan consisted of a vertical and a horizontal scan line intersecting 
at the fovea. The volume scan, covering 20 ° × 20 °, comprised 49 
parallel B-scans separated by 121 μm, whereby each B-scan was the 
average of 9 frames (automated real-time repetition rate = 9) con-
sisting of 512 A-scans.
 Each scan was reviewed by 2 independent assessors (A.E., 
M.S.Z.) for the presence of IRF or SRF. The presence of IRF, SRF 
or macular fluid (MF), a combination of SRF and IRF, was record-
ed for each monthly follow-up visit during the loading phase. For 
each type of fluid collection, subgroup analysis of CRT and BCVA 
was performed. CRT was determined automatically by the soft-
ware as the distance from the internal limiting membrane of the 
retina to the outer border of the retinal pigment epithelium, ex-
cluding any sub-retinal pigment epithelium structures like choroi-
dal neovascularization membranes.
 Ethics approval (KEK No. 093/13) to conduct this study was 
obtained from the local Ethics Committee, which is working in ac-
cordance with the ICH-GCP guidelines. The need for written con-
sent from each individual patient was waived because of the retro-
spective nature of the study. The data were analyzed with paired t 
test and one-way ANOVA as appropriate. p < 0.05 was considered 
statistically significant. Error bars in the graphs represent standard 
errors of the mean (SEM). Statistical analysis was performed using 
the Prism GraphPad ® software package (Prism 5; GraphPad Soft-
ware Inc., La Jolla, Calif., USA).
 Results 
 Thirty-one patients, seen between 2010 and 2012 at the 
Retinal Service of the Department of Ophthalmology at 
the University Hospital Bern, Switzerland, had complete 
data for 3 consecutive months and were evaluated in this 
study. The mean age of the patients at the time of diagno-
sis of exudative AMD was 77 years (range: 57–93). The 
mean BCVA at baseline was 50.9 letters (range: 5–86) 
with a CRT of 491 μm (range: 265–808). BCVA increased 
from a mean ± SD of 50.9 ± 16.4 letters at baseline to 57.5 
± 12.8 at month 3 (p = 0.003). CRT was 491 ± 138 μm at 
baseline and 374 ± 145 μm at month 3 (p < 0.0001). The 
changes in BCVA and CRT in our patient cohort during 
the loading phase with ranibizumab were similar to other 
published data  [8] and are summarized in  figure 1 .
 The percentage of eyes with any fluid 1 month after the 
third injection was 71% when assessed by volume scan 
and 61% with crosshair scan. The subgroup analysis 
showed that eyes with IRF (33%) or MF (31%) seemed to 
have a higher chance of complete resolution of fluid after 
3 intravitreal injections compared to eyes with SRF (22%). 
There was rapid improvement of BCVA in the MF group 
during the loading phase, from 46.4 ± 18.4 letters at base-
line to 54.0 ± 14.1 at month 3 ( fig. 2 a), whereas SRF pa-
tients displayed a slower visual recovery, but starting 
from better visual acuity, from 59.4 ± 13.3 letters at base-
line to 65.2 ± 9.1 at month 3 ( fig. 2 b). In the IRF group, 
the visual gain was 5.3 letters, from 50.0 ± 10.8 letters at 
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baseline to 55.3 ± 10.0 at month 3 ( fig. 2 c). Neither base-
line nor improvement of BCVA was statistically signifi-
cant between the groups (one-way ANOVA).
 The occurrence of pigment epithelium detachments 
(PED) was also investigated. In 17 eyes, there was a PED 
present at the onset of the treatment, which persisted 
throughout the loading phase. In 2 patients, a PED was 
present at the beginning of the observation period and 
disappeared in the course of the loading phase ( fig. 3 a–c). 
One patient developed a persisting PED during the load-
ing treatment, whereas 10 eyes never showed evidence of 
a PED. In 1 eye, a PED appeared after the first intravit-
real injection of ranibizumab but then subsequently dis-
solved after another injection ( fig. 3 d–f).
 Eyes without IRF or SRF at the conclusion of the load-
ing phase had a significantly larger decrease in CRT when 
compared to eyes with persistent IRF or SRF (p = 0.002). 
Whereas in the former group, CRT diminished by 226 ± 
159 μm, in the latter, it decreased by only 73 ± 94 μm. 
However, there was no difference in the change of BCVA 
between these 2 groups (p = 0.927), suggesting that per-
sisting fluid does not significantly affect visual acuity 
( fig. 4 ) early during treatment with ranibizumab.
 The overall sensitivity of crosshair scans to detect IRF 
or SRF when benchmarked against volume scans was 93% 
(n = 122). Crosshair scans were more sensitive to detect 
SRF (93%) than IRF (69%). A representative case in which 
IRF was missed on the crosshair scan is illustrated in  fig-
ure 5 .
 Discussion 
 In our study, we found a high percentage of eyes dis-
playing persisting IRF or SRF after initiation of treatment 
with ranibizumab. To our knowledge, this is the first re-
port showing the outcome after the initial loading phase 
with ranibizumab with regard to IRF or SRF. After 3 in-
jections, 71% of the eyes still displayed IRF or SRF. After 
1 injection of ranibizumab, 80% of the eyes had IRF or 
SRF, which is in keeping with recently reported data from 
the CATT study. In the CATT study, at 4 weeks, 161 of 
586 (27.5%) patients treated with ranibizumab had no 
fluid on OCT, and after 1 year, only 24% had no IRF or 
SRF on OCT in the ranibizumab treatment-as-needed 
group  [9] .
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 Fig. 1. Mean changes from baseline in vi-
sual acuity and CRT during the loading 
phase.  a Mean gain in ETDRS letters from 
baseline visual acuity at 1 through 3 months 
after treatment start. At each time point, 
the increase is significant compared to 
baseline BCVA: 4.3 letters at month 1 (p = 
0.012), 5.8 letters at month 2 (p = 0.031) 
and 6.6 letters at month 3 (p = 0.003).  b De-
crease in CRT compared to baseline. The 
decrease was 92 μm at month 1 (p = 0.0008), 
133 μm at month 2 (p < 0.0001) and 117 μm 
at month 3 (p < 0.0001). 
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 Fig. 2. Subgroup analysis of BCVA. BCVA 
is illustrated at baseline and 3 months after 
the first intravitreal injection. Subgroups 
were defined as eyes with both IRF and SRF 
(i.e. MF,  a ), SRF only ( b ), and IRF only ( c ). 
Baseline BCVA did not seem to differ be-
tween the subgroups (one-way ANOVA,
p = 0.160), nor did CRT (one-way ANOVA, 
p = 0.134). Letter gain and decrease in CRT 
were not statistically different between the 
subgroups (one-way ANOVA, p = 0.893 
and p = 0.308, respectively). 
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 Several salient OCT features during the loading phase 
of exudative AMD merit further discussion. Our data 
suggest that after the loading phase, only 29% of the pa-
tients display no SRF or IRF and that therefore, 71% of 
the patients will require further monthly injections. 
Whereas 20% of the patients were completely dry after the 
first injection, the proportion of patients displaying no 
IRF or SRF after the second or third injection increased 
only marginally to 29% after the third injection. Interest-
ingly, the presence or absence of fluid did not affect the 
visual recovery in the short loading phase, although the 
persistence of fluid in the long term can result in bad out-
a
b
c
d
e
f
 Fig. 3. Case histories representing different comportments of PED during the loading phase with ranibizumab. In case 1 ( a–c ), the PED 
present at baseline ( a ) gradually vanishes and is not detectable at the month 2 visit ( c ) any more. In the second case ( d–f ), a PED, not 
detectable at baseline ( d ), appears at the month 1 visit ( e ), but is no longer present a month later ( f ). 
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 Fig. 4. Subgroup analysis of BCVA and 
CRT based on the presence or absence of 
fluid at conclusion of the loading phase. 
Both subgroups had a similar increase in 
visual acuity ( a ). Interestingly, the quick 
return of CRT to the normal range ( b ) was 
not paralleled by a swifter visual recovery. 
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comes  [10] . There seems to be a large degree of variabil-
ity in the accumulation of IRF or SRF as the percentage of 
patients having been dry at any stage during the loading 
phase was 50% in the MF group, 23% in the SRF group 
and 33% in the IRF group.
 The decrease of CRT after the loading phase was sig-
nificantly larger in patients with no residual fluid at the 
end of the loading phase when compared to patients with 
persisting IRF or SRF. In all large studies investigating the 
effect of ranibizumab, 3 consecutive monthly injections 
appeared optimal and the majority of patients experi-
enced the most gain of visual acuity in this phase of treat-
ment  [11] . During the loading phase, the largest gain in 
visual acuity occurred after the first injection. This is in 
keeping with our data. However, persisting IRF or SRF 
did not influence the improvement in BCVA during the 
loading phase with ranibizumab in our study. Even 6 
months after the first injection, patients with persisting 
IRF or SRF did not have significantly worse visual acuity 
when compared to the group that was completely dry 
(data not shown). In the subgroup analysis, the location 
of the fluid neither influenced baseline visual acuity nor 
the gain in visual acuity.
 Information about the changes in different macular 
compartments with regard to treatment response to ra-
nibizumab is essential to identify parameters to guide 
treatment and retreatment criteria. In this study, we 
showed that SD-OCT provides an excellent tool with high 
resolution to identify the dynamics of IRF or SRF during 
the loading phase with ranibizumab in the treatment of 
exudative AMD. However, single crosshair OCT scans 
may fail to detect some cases with parafoveal exudative 
activity. Interestingly, this is particularly true after the 
first injection, possibly due to compartmentalization of 
fluid and the establishment of residual parafoveal cystoid 
spaces.
 In conclusion, analysis of OCT images during the 
loading phase with ranibizumab showed that the major-
ity of patients had persisting IRF or SRF. The presence of 
persisting IRF or SRF during treatment with ranibizumab 
is increasingly apparent due to the ability of SD-OCT to 
swiftly acquire high-resolution volume scans and detect 
even smaller fluid-filled spaces. We showed that persist-
ing fluid during the induction phase did not lead to a 
slower gain in BCVA when compared to eyes that were 
dry at the end of the loading phase.
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a
b
c
 Fig. 5. Representative case history illustrating the somewhat low-
er sensitivity of a crosshair scan to detect small amounts of IRF.  b , 
 c OCT scan along the green line. No IRF is visible. However, in the 
volume scan, on a horizontal scan taken slightly above the scan in 
 b , IRF is clearly present ( a ). 
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